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Abstract 
A genome-wide significant association has been reported between non-coding variants at the 
dopamine D2 receptor (DRD2) gene locus and schizophrenia. However, effects of identified 
schizophrenia risk alleles on DRD2 function are yet to be demonstrated. Using highly sensitive 
measures of allele-specific expression, we have assessed cis-regulatory effects associated with 
genotype at lead SNP rs2514218 on DRD2 expression in the adult human striatum. No significant 
differences were observed in the extent of allelic expression imbalance between samples that were 
genomic heterozygotes for rs2514218 (where cis-regulatory effects of the risk allele are compared 
with those of the non-risk allele within individual subjects) and samples that were homozygous for 
rs2514218 (where cis-regulatory effects of this SNP on each expressed DRD2 allele will be equal). We 
therefore conclude that rs2514218 genotype is not associated with large effects on overall DRD2 
RNA expression, at least in post-mortem adult striatum. Alternative explanations for the genetic 
association between this variant and schizophrenia include effects on DRD2 that are transcript-
specific, restricted to minor DRD2-expressing cell populations or elicited only under certain 
physiological circumstances, or mediation through effects on another gene (or genes) at the locus. 
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Introduction 
The dopamine D2 receptor is a primary therapeutic target of all current antipsychotic drugs [1]. It is 
encoded by a single gene, DRD2, which gives rise to two major receptor isoforms (D2-long and D2-
short) through alternative RNA splicing [2]. An early focus of candidate gene association studies [e.g. 
3, 4], DRD2 has been the subject of renewed interest as a potential schizophrenia susceptibility gene 
following observation of genome-wide significant association between schizophrenia and variants at 
the DRD2 locus in a large genome-wide association study (GWAS) [5]. The single nucleotide 
polymorphism (SNP) at the locus exhibiting most significant association with schizophrenia in that 
study was rs2514218 (P = 2.75 X10-11 in the entire sample), a non-coding variant located 47kb 
upstream of the most 5’ known DRD2 exon. This association has been further substantiated in a 
recent, enlarged GWAS of schizophrenia [6], where fine-mapping has indicated that rs2514218 is the 
SNP at the locus with the highest posterior probability (0.69) of being the causal variant.  
 
The schizophrenia risk (C-) allele of rs2514218 is reported to be associated with impaired striatal 
function [7] and antipsychotic treatment response [8, 9]. Although these findings are consistent with 
effects on subcortical dopamine function, the effect on DRD2 associated with rs2514218 genotype is 
currently unclear. Given its location in non-coding sequence, we hypothesized that rs2514218, or 
other variants in linkage disequilibrium with it, alter the expression of DRD2 in the human brain. In 
order to test this hypothesis, we used highly sensitive measures of allele-specific expression to 
assess effects of rs2514218 genotype on the cis-regulation of DRD2 in the adult striatum, a region 
where DRD2 is prominently expressed, and where D2 receptor occupancy predicts the therapeutic 
response to antipsychotic drugs [10].   
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Materials and Methods 
Brain samples  
Frozen caudate tissue was obtained post-mortem from 120 unrelated adults from the London 
Neurodegenerative Diseases Brain Bank (U.K.). All subjects were free from psychiatric or 
neurological diagnosis at the time of death. Genomic DNA was extracted from all samples using 
standard phenol/chloroform procedures. Total RNA was extracted using Tri-Reagent (Thermo Fisher 
Scientific), according to manufacturer instructions. RNA samples were treated with TURBO DNase 
(Thermo Fisher Scientific) prior to reverse transcription and did not yield a PCR product in the 
absence of a reverse transcription step. Approximately 1 µg of total RNA was reverse transcribed 
with SuperScript III and random decamers (Thermo Fisher Scientific). Resulting cDNA was diluted 1:7 
prior to use. 
 
Genotyping 
Samples were genotyped for schizophrenia risk SNP rs2514218 and DRD2 exonic SNPs rs6277 and 
rs7116768 (used for measures of DRD2 allele-specific expression) by single base primer extension 
using SNaPshot® chemistry (Thermo Fisher Scientific) and PCR-amplified genomic DNA. Primer 
sequences are provided in Supplementary Table S1. There was no significant (P < 0.05) deviation 
from Hardy-Weinberg equilibrium in the genotype distribution of any variant. Linkage disequilibrium 
(D’) between genotyped SNPs in the 120 samples was calculated using Haploview version 4.2 [11]. 
 
Measurement of DRD2 allele-specific expression 
Measures of allele-specific expression typically make use of SNPs in exonic (i.e. expressed) sequence 
as endogenous tags to discriminate and relatively quantify the RNA transcribed from each 
chromosomal copy of a gene in heterozygous subjects. Departure from the expected 1:1 ratio of 
allelic expression in any given sample indicates heterozygous cis-regulatory influences operating on 
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that gene [12]. A major advantage of this ‘within-subjects’ approach is that it measures variable cis-
effects on gene expression while controlling for confounding influences (e.g. trans-effects of other 
genes, environmental exposures and tissue variables such as RNA quality), which are expected to 
impact on both gene copies equally. 
 
Samples identified as genomic heterozygotes for SNPs rs6277, located in the penultimate exon of 
most protein-coding DRD2 RNA transcripts, and SNP rs7116768, located in a 5’ exon utilised by a 
smaller subset of DRD2 transcripts, were used to measure DRD2 allelic expression. Known 
demographics for these samples are provided in Supplementary Table S2. The position of these SNPs 
in relation to Ensembl transcripts is shown in Figure 1. Sequence containing rs6277 or rs7116768 
was PCR-amplified from cDNA alongside genomic DNA from the same heterozygous subjects using 
primers based on single exon sequence (Supplementary Table S1). PCR products were treated with 
shrimp alkaline phosphatase and exonuclease I (New England Biolabs) to inactivate nucleotides and 
primers for downstream steps. Alleles of each SNP were discriminated and relatively quantified by 
SNaPshot® primer extension (Thermo Fisher Scientific), using extension primers detailed in 
Supplementary Table S1. Reaction products were electrophoresed on an Applied Biosystems 3130xl 
Genetic Analyzer and peak heights of allele-specific extended primers were determined using 
GeneMarker software (SoftGenetics). Peak heights, representing the relative abundance of each 
allele, were used to calculate an allele ratio for each reaction. The average allele ratio from all 
genomic DNA samples on each plate was used as a correction factor for all genomic DNA and cDNA 
allele ratios, since this can be assumed to reflect a perfect 1:1 ratio of the two alleles and can 
therefore be used to correct for any inequalities in allelic representation specific to the assay [12]. 
Four technical replicates were performed for each cDNA sample, alongside H2O as a negative 
control. Any samples showing poor reproducibility in cDNA allele ratios (standard deviation / mean > 
0.25) were excluded from further analyses. 
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PLEASE INSERT FIGURE 1 AROUND HERE 
 
Testing effect of rs2514218 genotype on DRD2 allelic expression  
D’ between rs6277 and rs2514218 was 0.51 in our samples, and 0.65 between rs7116768 and 
rs2514218.  This modest level of linkage disequilibrium between the SNPs used to assay DRD2 allele-
specific expression and the schizophrenia risk SNP means that, for any given sample, the phase 
between expressed DRD2 alleles and the risk allele is uncertain. We therefore assessed potential cis-
regulatory effects on DRD2 associated with the rs2514218 risk allele by comparing the mean 
deviation from the average (1:1) genomic allele ratio observed in rs2514218 heterozygotes (where 
any cis-regulatory effects of the risk allele are compared with those from the non-risk allele) and 
rs2514218 homozygotes (where cis-regulatory effects of rs2514218 alleles are equal). Comparisons 
were performed by two-tailed t-tests using SPSS 25.0 software. There was no significant difference 
in the variance of allelic expression imbalance between rs2514218 heterozygotes and homozygotes 
at either expressed SNP (Levene’s test P > 0.05). 
 
Results 
Allele-specific expression at DRD2 SNP rs6277 was assessed in 39 heterozygous samples. Of these, 
18 were additionally heterozygous for schizophrenia risk SNP rs2514218, while 21 were 
homozygous. Figure 2 shows allelic expression ratios in cDNA from rs2514218 homozygotes and 
heterozygotes, alongside allelic ratios derived from genomic DNA from the same subjects. Two 
samples that were heterozygous for schizophrenia risk SNP rs2514218 exhibited pronounced allelic 
expression imbalance, with increased relative expression of the rs6277 A-allele by 35% and 40%. 
However, the mean deviation from the expected 1:1 ratio of the two alleles was similar for 
rs2514218 homozygotes, at 10%, and heterozygotes, at 12% (P = 0.46). 
 
7 
 
PLEASE INSERT FIGURE 2 AROUND HERE 
SNP rs7116768 is located within the most 5’ DRD2 exon, and the closest known exon to 
schizophrenia risk SNP rs2514218. This exon is predicted to be contained within two Ensembl DRD2 
transcripts, including DRD2-201 (ENST00000346454.7), encoding D2-short. Allele-specific expression 
at rs7116768 was assessed in 23 heterozygous samples. Of these, 7 were additionally heterozygous 
for schizophrenia risk SNP rs2514218 and 16 were homozygous. With the exception of one rs251421 
heterozygote, which exhibited an allelic expression imbalance of 18%, all samples displayed cDNA 
allele ratios close to the 1:1 genomic average, with a mean deviation of 5% in rs251421 
heterozygotes and 2% in rs251421 homozygotes (P = 0.56). 
PLEASE INSERT FIGURE 3 AROUND HERE 
 
Discussion 
We have used highly sensitive measures of allele-specific expression to assess cis-regulatory effects 
associated with rs2514218 genotype on DRD2 expression in the adult human striatum. Although a 
small number of rs2514218 heterozygotes displayed pronounced allelic expression imbalance, the 
majority exhibited cDNA allele ratios similar to those observed in rs2514218 homozygotes, where 
cis-regulatory effects of this SNP on each expressed DRD2 allele will be equal. We therefore 
conclude that rs2514218 genotype is not associated with consistent effects on overall DRD2 RNA 
expression, at least in post-mortem adult striatum.  
 
The allele-specific expression method is considerably more powerful than standard expression 
quantitative trait loci (eQTL) approaches for detecting cis-regulatory variation because it controls 
potential trans-acting confounders that will act on both chromosomal copies of an expressed gene 
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to the same extent (i.e. affecting total, but not allele-specific, expression). Indeed, eQTL approaches 
have been found to require up to 8 times more samples than allele-specific expression measures to 
detect the effects of the same cis-regulatory variants [13]. However, in finding no evidence for an 
association between rs2514218 genotype and DRD2 expression, our data are broadly consistent with 
publicly available eQTL data generated from post-mortem human brain tissue. Thus, in the 
BRAINEAC database (available at http://www.braineac.org/) [14], which includes 10 adult brain 
regions, genotype at rs2514218 is associated with more significant effects on the expression of 
several other genes at the DRD2 locus (e.g. REXO2, HTR3A, NCAM1, TTC12 and ANKK1) than on 
DRD2 itself, although in no case is the evidence strong (smallest P = 0.00087 [uncorrected] for REXO2 
expression in putamen). Similarly, rs2514218 is not associated with significant effects on the 
expression of any gene in any of the 13 adult brain regions included in the GTEx version 7 release 
(data available at https://gtexportal.org/home/) [15], although significant (but opposing) effects of 
the risk allele on DRD2 expression are observed in esophagus and skeletal muscle. SNP rs2514218 is 
not associated with significant effects on the expression of any gene in the adult dorsolateral 
prefrontal cortex in the BrainSeq phase 1 data from the Lieber Institute (data available at 
http://eqtl.brainseq.org/phase1/) [16], while the recent large-scale eQTL mapping study performed 
by the PsychENCODE Consortium in adult prefrontal cortex (data available at 
http://resource.psychencode.org/) [17], identified no variants associated with altered DRD2 
expression at a false discovery rate (FDR) < 0.05. In addition, we found no evidence that rs2514218 
or any other common variants are eQTL (at FDR < 0.05) for DRD2 in second trimester human fetal 
brain [18], despite detection of DRD2 expression at this early stage of development (data available at 
https://doi.org/10.6084/m9.figshare.6881825).       
 
Given the current lack of evidence for an effect of rs2514218 genotype on DRD2 expression in post-
mortem brain, alternative explanations for the highly significant association between this SNP and 
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schizophrenia are required. As we used expressed SNPs common to multiple DRD2 mRNA transcripts 
to assay allele-specific expression, it is possible that effects of rs2514218 genotype are restricted to 
specific transcripts that constitute only a fraction of the DRD2 expression measured. It is also 
possible that effects on DRD2 are specific to a minority cell population within the striatum (or other 
brain region), or that these effects are elicited only in circumstances of neural activity that are not 
captured in post-mortem tissue. These possibilities may be addressed in future studies through RNA 
sequencing (providing transcript-specific measures), single cell analyses and in vitro assessments. 
However, while DRD2 is a prime functional candidate for schizophrenia, a fourth possibility – that 
susceptibility is mediated through a different gene (or genes) at the locus – should not be 
discounted.   
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Figure Legends 
Figure 1. Position of expressed single nucleotide polymorphisms rs6277 and rs7116768, used to 
assay DRD2 allele-specific expression in this study, in relation to DRD2 transcripts annotated by 
Ensembl (release 95). Location in Mb on chromosome 11 is shown according to Genome Reference 
Consortium Human Build 38. Schizophrenia risk SNP rs2514218 is located at 113.52Mb.  
 
Figure 2. Allele ratios at expressed DRD2 SNP rs6277 in the caudate of adult subjects who are either 
homozygous or heterozygous for schizophrenia risk SNP rs2514218. Data points represent the 
average allele ratio in genomic DNA or cDNA from each sample. Mean allele ratios are indicated by 
horizontal lines. There is no significant difference in the extent of allelic expression imbalance 
(departure from the average 1:1 genomic ratio) between cDNA from rs2514218 homozygotes and 
rs2514218 heterozygotes (P = 0.46). 
 
Figure 3. Allele ratios at expressed DRD2 SNP rs7116768 in the caudate of adult subjects who are 
either homozygous or heterozygous for schizophrenia risk SNP rs2514218. Data points represent the 
average allele ratio in genomic DNA or cDNA from each sample. Mean allele ratios are indicated by 
horizontal lines. There is no significant difference in the extent of allelic expression imbalance 
(departure from the average 1:1 genomic ratio) between cDNA from rs2514218 homozygotes and 
rs2514218 heterozygotes (P = 0.56). 



